Polyrizon’s intranasal naloxone formulation achieved 94.6% deposition in the nasal vestibule and upper turbinate region, compared with 79.6% for the commercial reference product, according to a study conducted at the University of Parma’s Biopharmanet‑TEC research center. The study used a validated Koken® LM‑005 silicone nasal cast and quantitative image analysis to measure regional deposition.
In the lower turbinate region, Polyrizon’s formulation delivered 5.4% deposition versus 20.4% for the reference product, underscoring the platform’s superior mucoadhesion and targeted delivery. The results demonstrate the Trap‑and‑Target™ technology’s ability to precisely target the highly vascularized upper nasal region, a key site for rapid systemic absorption of naloxone.
CEO Tomer Izraeli said, "This evaluation demonstrates the ability of our platform technology to modulate and control nasal deposition patterns compared to an established commercial product." He added, "We believe that these outcomes further validate the potential of our T&T hydrogel platform and highlight its unique advantages in intranasal drug delivery." The study marks a significant operational milestone for Polyrizon’s naloxone program and supports the company’s strategy to expand beyond barrier sprays into active pharmaceutical ingredient delivery.
Polyrizon is a development‑stage biotechnology firm with a market capitalization of about $21.6 million and negative EBITDA. While the study does not yet translate into revenue, it could broaden the company’s product pipeline and create licensing or commercialization opportunities in the opioid overdose reversal market. The company maintains a strong cash position and no debt, positioning it to pursue further development and potential partnerships.
The study’s findings reinforce Polyrizon’s competitive positioning in the intranasal drug delivery space and may influence future investment decisions regarding the company’s pipeline and strategic partnerships. The company’s focus on the T&T platform could open new avenues for rapid‑acting medications beyond naloxone, potentially expanding its market reach.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.